Free tool
Cell therapy stocks
We cover 4 companies grouped under the Cell therapy theme. The median market value in the group is $11.35M. Across the group, the median move over the past trading day is −4.54%. Price change over the past year runs from −96.0% to −49.2% across the middle 80 percent of the group, with a median of −78.7%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
4 of 86 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| 0NLV.L | FamiCord AG | 2.78 EUR | −1.55% | −53.28% | −62.93% |
| 311A.T | NPT Co Ltd | 680.00 JPY | 0.00% | −2.86% | −43.33% |
| CYP.AX | Cynata Therapeutics Limited | 0.01 AUD | −8.33% | −96.90% | −94.50% |
| CHM.AX | Chimeric Therapeutics Limited | 0.01 AUD | −76.74% | −95.00% | −96.67% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.